Innovative Medicine
-
-
XARELTO® (rivaroxaban) Demonstrates Comparable Efficacy to Standard of Care for the Treatment and Secondary Prevention of Venous Blood Clots in Patients with Symptomatic Pulmonary Embolism in Pivotal Phase 3 Study
Rivaroxaban Showed Similar Safety Profile with Significantly Fewer Major Bleeds vs. Standard of Care Phase 3 Study Presented as Late-Breaker at the American College of Cardiology Annual Scientific Sessions and Published in the New England Journal of Medicine -
-
Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer
Second ZYTIGA Phase 3 Study to be Unblinded, Based on Unanimous Recommendation of Independent Data Monitoring Committee -
-
New Patient Guidebook, “Live Healthier – Weight Loss Options for Treating Obesity,” Now Offered by the American College of Physicians Foundation
Guidebook and DVD Help Patients Learn About Obesity and Available Treatment Options -
Alzheimer’s Challenge 2012: Seeking New Tools To Help Improve Alzheimer’s Care
New Challenge Seeks Simple, Widely-Adaptable Tools to Track Alzheimer’s Progression and Support HHS “Triple Aim” of Better Care and Better Health at Lower Cost -
Janssen Healthcare Innovation Announces JANSSEN CONNECTED CARE CHALLENGE to Spur Innovation in Patient Care
Janssen Connected Care Challenge seeks transformational transition care ideas and offers awards totaling $250,000 to develop winning solutions -
Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego
Novel Life Science Innovation Center To Spur Science By Supporting Early-Stage Life Science Industry